Jenburkt Pharmaceuticals (BOM:524731) ROCE %: 27.28% (As of Mar. 2026)


BOM:524731 Jenburkt Pharmaceuticals Ltd BOM:524731
81 GF Score
Price ₹1,116.30
GF Value ₹1,112.47
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Jenburkt Pharmaceuticals ROCE %?

Jenburkt Pharmaceuticals BOM:524731 -0.77% 81 ROCE % is 27.28% as of Mar. 2026. GuruFocus rates BOM:524731 with a GF Score™ of 81/100 and a GF Value™ of ₹1,112.47 (Fairly Valued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jenburkt Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 27.28%.

Jenburkt Pharmaceuticals  (BOM:524731) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jenburkt Pharmaceuticals ROCE % Related Terms

Jenburkt Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Jenburkt Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jenburkt Pharmaceuticals ROCE % Chart

Jenburkt Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.88 26.78 25.77 27.22 24.71

Jenburkt Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.94 23.21 30.70 17.88 27.28
BOM:524731
81GF Score
Jenburkt Pharmaceuticals Ltd BOM:524731
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jenburkt Pharmaceuticals ROCE % Calculation

Jenburkt Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=469.809/( ( (1961.86 - 188.194) + (2260.126 - 231.467) )/ 2 )
=469.809/( (1773.666+2028.659)/ 2 )
=469.809/1901.1625
=24.71 %

Jenburkt Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=553.496/( ( (0 - 0) + (2260.126 - 231.467) )/ 1 )
=553.496/( ( 0 + 2028.659 )/ 1 )
=553.496/2028.659
=27.28 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 27.28% mean?
Jenburkt Pharmaceuticals (BOM:524731) has a ROCE % of 27.28% as of Mar. 2026.
Is Jenburkt Pharmaceuticals' ROCE % too high?
Jenburkt Pharmaceuticals' current ROCE % is 27.28%. The Drug Manufacturers industry median ROCE % is 7.03. Jenburkt Pharmaceuticals' value of 27.28% is 288.1% above this industry median. Overall, Jenburkt Pharmaceuticals has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jenburkt Pharmaceuticals' ROCE % compare to ZTS and UTHR?
Jenburkt Pharmaceuticals' ROCE % of 27.28% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Jenburkt Pharmaceuticals' value of 27.28% is 288.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jenburkt Pharmaceuticals's current ROCE % of 27.28% is 288.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jenburkt Pharmaceuticals's current ROCE % is 27.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenburkt Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals (BOM:524731) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,112.47, compared to a current price of ₹1,116.30 — trading 0.3% above its estimated fair value. The current ROCE % is 27.28% and 288.1% above the Drug Manufacturers industry median of 7.03. Jenburkt Pharmaceuticals' overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Jenburkt Pharmaceuticals (BOM:524731), the current ROCE % is 27.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jenburkt Pharmaceuticals (BOM:524731) Overvalued in 2026?

Based on GuruFocus' analysis, Jenburkt Pharmaceuticals stock appears to be overvalued. The current stock price of ₹1,116.30 is trading 0.3% above its estimated GF Value™ of ₹1,112.47. GuruFocus considers Jenburkt Pharmaceuticals to be Fairly Valued.

Key valuation signals for BOM:524731:

  • ROCE %: 27.28%
  • GF Value™: ₹1,112.47 vs. price of ₹1,116.30 (0.3% above fair value)
  • GF Score™: 81/100 with 1 warning sign
  • Industry Position: 288.1% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:524731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jenburkt Pharmaceuticals Business Description

Address 93, Jayprakash Road, Nirmala Apartments, Andheri (West, Mumbai, MH, IND, 400058
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.
81GF Score

Get the complete analysis for BOM:524731

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,116.30
Price
₹1,112.47
GF Value